Valbenazine

Phase 3Active

0 watching 0 views this week📈 Rising

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Chorea, Huntington

Conditions

Chorea, Huntington

Trial Timeline

Sep 18, 2020 → Mar 1, 2026

NCT ID

NCT04400331

About Valbenazine

Valbenazine is a phase 3 stage product being developed by Neurocrine Biosciences for Chorea, Huntington. The current trial status is active. This product is registered under clinical trial identifier NCT04400331. Target conditions include Chorea, Huntington.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (8)

NCT ID	Phase	Status	Start	Completion	Indication
NCT07105111	Approved	Recruiting	Aug 29, 2025	Apr 1, 2027	Schizophrenia
NCT05053321	Phase 1	Withdrawn	Oct 18, 2024	Oct 18, 2025	Tardive Dyskinesia
NCT06312189	Phase 3	Recruiting	Apr 24, 2024	Apr 1, 2026	Chorea, Huntington
NCT05859698	Approved	Completed	May 9, 2023	Dec 27, 2024	Schizophrenia
NCT04400331	Phase 3	Active	Sep 18, 2020	Mar 1, 2026	Chorea, Huntington
NCT03444038	Phase 2	Completed	Feb 8, 2018	Jul 12, 2019	Tourette Syndrome
NCT02879578	Phase 2	Completed	Jul 25, 2016	Nov 1, 2017	Tourette Syndrome
NCT02736955	Phase 3	Completed	Jun 13, 2016	Jun 30, 2017	Tardive Dyskinesia

Competing Products

2 competing products in Chorea, Huntington

See all competitors

Product	Company	Stage	Hype Score
Valbenazine + Placebo	Neurocrine Biosciences	Phase 3	74
Valbenazine	Neurocrine Biosciences	Phase 3	74

Other Products from Neurocrine Biosciences

Valbenazine Oral CapsuleApproved

ValbenazineApproved

Valbenazine + Placebo oral capsuleApproved